Literature DB >> 20733303

Voxel-based analysis of amyloid positron emission tomography probe [C]BF-227 uptake in mild cognitive impairment and alzheimer's disease.

He Shao1, Nobuyuki Okamura, Kentaro Sugi, Shozo Furumoto, Katsutoshi Furukawa, Manabu Tashiro, Ren Iwata, Hiroshi Matsuda, Yukitsuka Kudo, Hiroyuki Arai, Hiroshi Fukuda, Kazuhiko Yanai.   

Abstract

AIM: To determine early brain changes in the distribution of an amyloid positron emission tomography (PET) probe, (11)C-labeled BF-227 or [(11)C]BF-227, in order to accurately predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). PATIENTS AND METHODS: Amyloid plaque burden was evaluated using [(11)C]BF-227 PET in AD, MCI and aged normal controls. A voxel-based analysis of [(11)C]BF-227 PET images was performed to characterize the culprit brain lesion in patients with MCI who were destined to progress to AD, referred to as MCI converters (MCI-C). In addition, binding characteristics of BF-227 to amyloid deposits were examined using postmortem AD brain samples.
RESULTS: Voxel-based statistical analyses of the BF-227 PET images clearly demonstrated an abnormal distribution of BF-227 mainly in the posterior association area in MCI-C and patients with AD. BF-227 uptake in the lateral temporal cortex was consistently observed in almost all MCI-C and patients with AD, and it distinguished MCI-C from MCI nonconverters. BF-227 binding strongly correlated with dense amyloid-β protein plaque density, but not with diffuse plaque density in the frontal cortex.
CONCLUSION: BF-227 uptake in the lateral temporal cortex is a reliable indicator that can be used for predicting prognosis in patients with MCI.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733303     DOI: 10.1159/000318754

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  6 in total

1.  A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography.

Authors:  Shozo Furumoto; Nobuyuki Okamura; Katsutoshi Furukawa; Manabu Tashiro; Yoichi Ishikawa; Kentaro Sugi; Naoki Tomita; Masaaki Waragai; Ryuichi Harada; Tetsuro Tago; Ren Iwata; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

2.  Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Authors:  V Camus; P Payoux; L Barré; B Desgranges; T Voisin; C Tauber; R La Joie; M Tafani; C Hommet; G Chételat; K Mondon; V de La Sayette; J P Cottier; E Beaufils; M J Ribeiro; V Gissot; E Vierron; J Vercouillie; B Vellas; F Eustache; D Guilloteau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-18       Impact factor: 9.236

3.  Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis.

Authors:  Eun Hyun Seo; Woon Yeong Park; Il Han Choo
Journal:  Psychiatry Investig       Date:  2017-03-06       Impact factor: 2.505

4.  Correlation between β-amyloid deposits revealed by BF-227-PET imaging and brain atrophy detected by voxel-based morphometry-MR imaging: a pilot study.

Authors:  Nobuhisa Maeno
Journal:  Nucl Med Commun       Date:  2019-09       Impact factor: 1.690

5.  Amyloid-β probes: Review of structure-activity and brain-kinetics relationships.

Authors:  Todd J Eckroat; Abdelrahman S Mayhoub; Sylvie Garneau-Tsodikova
Journal:  Beilstein J Org Chem       Date:  2013-05-28       Impact factor: 2.883

Review 6.  A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.

Authors:  Daniela Perani; Perani Daniela; Orazio Schillaci; Schillaci Orazio; Alessandro Padovani; Padovani Alessandro; Flavio Mariano Nobili; Nobili Flavio Mariano; Leonardo Iaccarino; Iaccarino Leonardo; Pasquale Anthony Della Rosa; Della Rosa Pasquale Anthony; Giovanni Frisoni; Frisoni Giovanni; Carlo Caltagirone; Caltagirone Carlo
Journal:  Biomed Res Int       Date:  2014-03-19       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.